Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novaccess Global Inc XSNX

Healthcare Biotechnology
NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is... see more

Recent & Breaking News (OTCPK:XSNX)

NovAccess Global Announces Fireside Chat with Board Member Perspectives

Accesswire October 20, 2022

NovAccess Global Announces Fireside Chat Series for the Investment Community

Accesswire September 29, 2022

NovAccess Global Announces Effectiveness of Form S-1 Registration Statement

Accesswire September 22, 2022

NovAccess Global Announces Uplisting to OTCQB

Accesswire August 10, 2022

CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1

Accesswire July 19, 2022

NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1

Accesswire July 19, 2022

NovAccess Global CEO Dwain Irvin Featured on MoneyTV

Accesswire June 14, 2022

This Week on MoneyTV with Donald Baillargeon, 6/10

Accesswire June 10, 2022

NovAccess Global to Participate in LD Micro Invitational XII Conference

Accesswire May 19, 2022

NovAccess Global Stock Redemption and Expanded Board of Directors Reinforces Shareholder Value and Positions the Company to Accelerate Objectives

Accesswire March 17, 2022

NovAccess Global, Inc.'s CEO to attend BIO Conference in New York

Accesswire February 15, 2022

NovAccess Global, Inc. Names Neil Laird, Chief Financial Officer

Accesswire December 8, 2021

NovAccess Global, Inc. Expands Advisory Board

Accesswire October 6, 2021

NovAccess Global, Inc. CEO Interviewed On MoneyTV

Accesswire September 15, 2021

This Week on MoneyTV with Donald Baillargeon, 9/10

Accesswire September 10, 2021

Innovest Global Completes Sale of StemVax Therapeutics to NovAccess Global

Accesswire September 10, 2020

NovAccess Global Acquires StemVax Therapeutics from Innovest Global

Accesswire September 9, 2020

Innovest Global Enters into Agreement for the Sale of StemVax Therapeutics to XsunX, Inc.

Accesswire August 11, 2020

XsunX, Inc. Joins the Stock Day Podcast to Discuss Goals for 2019

Accesswire June 11, 2019

Uptick Newswire Hosts XsunX, Inc. on the Stock Day Podcast to Discuss Increasing Potential in California for Renewable Energy Companies

GlobeNewswire February 27, 2019